7682436

Source:http://linkedlifedata.com/resource/pubmed/id/7682436

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0021747, umls-concept:C0055599, umls-concept:C0079747, umls-concept:C0441772
pubmed:issue	3
pubmed:dateCreated	1993-5-19
pubmed:abstractText	Alpha interferon (IFN) is an effective single agent for patients with low-grade lymphoma, but until 1982 had not been integrated with standard chemotherapy for these patients. Since relapse from complete remission (CR) is the rule for patients with advanced stage low-grade lymphoma, a maintenance IFN schedule was explored for patients in CR.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9007735
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Bleomycin, http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Interferon Type I, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/Prednisone, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
pubmed:status	MEDLINE
pubmed:month	Mar
pubmed:issn	0923-7534
pubmed:author	pubmed-author:CabanillasFF, pubmed-author:GuttermanJ UJU, pubmed-author:HagemeisterF BFB, pubmed-author:McLaughlinPP, pubmed-author:RedmanJ RJR, pubmed-author:RodriguezM AMA, pubmed-author:RomagueraJ EJE, pubmed-author:SwanFFJr, pubmed-author:TaylorSS, pubmed-author:VelasquezW SWS
pubmed:issnType	Print
pubmed:volume	4
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	205-11
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:7682436-Adult, pubmed-meshheading:7682436-Aged, pubmed-meshheading:7682436-Aged, 80 and over, pubmed-meshheading:7682436-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:7682436-Bleomycin, pubmed-meshheading:7682436-Combined Modality Therapy, pubmed-meshheading:7682436-Cyclophosphamide, pubmed-meshheading:7682436-Doxorubicin, pubmed-meshheading:7682436-Female, pubmed-meshheading:7682436-Follow-Up Studies, pubmed-meshheading:7682436-Humans, pubmed-meshheading:7682436-Interferon Type I, pubmed-meshheading:7682436-Interferon-alpha, pubmed-meshheading:7682436-Lymphoma, Non-Hodgkin, pubmed-meshheading:7682436-Male, pubmed-meshheading:7682436-Middle Aged, pubmed-meshheading:7682436-Neoplasm Staging, pubmed-meshheading:7682436-Prednisone, pubmed-meshheading:7682436-Recombinant Proteins, pubmed-meshheading:7682436-Survival Rate, pubmed-meshheading:7682436-Vincristine
pubmed:year	1993
pubmed:articleTitle	CHOP-Bleo plus interferon for stage IV low-grade lymphoma.
pubmed:affiliation	Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't